This study is in progress, not accepting new patients
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Loxo Oncology, Inc.
- Links
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)
- ID
- NCT04965493
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 600 study participants
- Last Updated